To evaluate the feasibility of conducting a prospective, randomized trial comparing early high -frequency oscillatory ventilation ( HFOV ) to synchronized intermittent mandatory ventilation ( SIMV ) in very low birth weight ( VLBW ) premature infants. This pilot study evaluated two ventilator management protocols to determine how well they could be implemented in a multicenter clinical trial.
SETTING:
Seven tertiary -level intensive care nurseries with previous experience with both HFOV and flow -triggered SIMV.
PATIENTS:
Fifty infants weighing 501 to 1200 g, less than 4 hours of age, who had received one dose of surfactant and required ventilation with mean airway pressure 6 cm H 2 O and F I O 2 0.25, and had an anticipated duration of ventilation greater than 24 hours.
INTERVENTIONS:
Patients were stratified by birth weight and prenatal steroid status, then randomized to either HFOV or SIMV with tidal volume monitoring. Ventilator management for patients in both study arms was strictly governed by protocols that included optimizing lung inflation and blood gases, weaning strategies, and extubation criteria.
MEASUREMENTS:
Data were collected using the tools planned for the larger collaborative study. Protocol compliance was closely monitored, with successive changes in the protocol made as necessary to improve clarity and increase compliance. The incidence of major neonatal adverse outcomes was recorded.
MAIN RESULTS:
Data are presented for 24 HFOV and 24 SIMV infants ( two infants, twins, were withdrawn from the study at parent's request ). Nineteen of the 24 HFOV infants and 20 of the 24 SIMV infants survived to 36 weeks corrected age. Age at final extubation for survivors was 16 16 ( mean SD ) days for HFOV infants and 24 24 days for SIMV infants. At 36 weeks corrected age, 14 of the 19 HFOV survivors were extubated and in room air, whereas 5 required supplemental oxygen. In comparison, 6 of the 20 SIMV survivors were extubated and in room air, whereas 14 required supplemental oxygen. Grade III / IV IVH and / or periventricular leukomalacia occurred in 2 HFOV and 2 SIMV patients.
Overall compliance with the ventilator protocols was 82% for the SIMV protocol, and 88% for the HFOV protocol.
CONCLUSIONS:
The preliminary outcome data supports conducting the large randomized trial, which began in July of 1998. The protocols for the
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INTRODUCTION
Very low birth weight (VLBW) infants frequently require mechanical ventilation. Despite the use of antenatal steroids and surfactant, the incidence of chronic lung disease (CLD, usually defined as the need for supplemental oxygen at either 1 month or 36 weeks corrected age), in these infants remains high. 1 There are currently multiple ventilatory modes available for managing VLBW infants, but relatively little data about the optimal ventilatory strategy for applying these modes. This is due, in part, to the recent rapid proliferation of different ventilator modes. Currently available ventilator options include multiple``conventional'' modes that deliver physiologic tidal volumes at physiologic breathing rates, as well as several high-frequency modes that achieve gas exchange by mechanisms other than delivery of tidal breaths. The most common forms of high-frequency ventilation (HFV) include high-frequency oscillatory ventilation (HFOV), high-frequency jet ventilation (HFJV), and high-frequency flow interruption. 2 There is considerable evidence that HFV, which maintains ventilation at high frequencies and extremely small tidal volumes, causes less lung injury than does tidal ventilation. Many animal studies have demonstrated that in diseases characterized by atelectasis, such as respiratory distress syndrome (RDS), HFOV produces better lung inflation and less lung damage than does tidal ventilation. 3 ± 9 These studies show that HFOV improves gas exchange in the immature or acutely injured lung, and reduces pulmonary injury by avoiding the large changes in intrapulmonary pressure and volume necessitated by tidal ventilation. HFOV appears to be particularly beneficial when started shortly after birth, before significant lung damage has been caused by tidal ventilation. 6 Although different modes of HFV are used extensively for the treatment of VLBW neonates with respiratory failure, it is unclear whether HFV, when begun shortly after birth, is superior to the modern modes of tidal ventilation for these infants. There are no published studies that have compared HFV to the modern patienttriggered, or synchronous, modes of tidal ventilation. In addition, most published studies of HFV have focused on larger infants, were performed before the release of exogenous surfactant for clinical use, or applied HFV for only a few days. 10 ± 15 Recent animal studies have demonstrated synergy between HFOV and surfactant treatment in RDS. 16, 17 However, only three clinical trials have compared HFV to tidal ventilation in infants treated with surfactant. Gerstmann et al. 18 found that survival without need for oxygen at 30 days was 71% in the HFOV group and 56% in the tidal ventilation group (P<0.02). Similarly, Keszler et al. 19 found that infants randomized to HFJV were significantly less likely than those randomizd to tidal ventilation to require oxygen at 36 weeks corrected age or at discharge from the hospital. Thome et al. 15 , however, found no differences in respiratory outcomes in their trial of 289 infants who were randomized to high-frequency flow interruption or tidal ventilation with high-rate conventional ventilation. Some, but not all, of the patients in Thome's trial who were treated with conventional ventilation were treated with a patient-triggered mode and/or with tidal volume monitoring.
All three of the above studies were limited by the fact that they compared HFV to intermittent mandatory ventilation (IMV), rather than to a patient-triggered mode of ventilation. There is some evidence that the newer patient-triggered modes of ventilation, such as synchronized intermittent mandatory ventilation (SIMV) are superior to IMV, both in consistency of delivered tidal breath and in clinical outcome.
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Continuous tidal volume monitoring is another potential advantage of many of the newer modes of tidal ventilation. The ability to continuously monitor delivered tidal volume offers, at least theoretically, a significantly safer way to deliver tidal breaths. None of the prior trials of HFV have compared HFV to tidal ventilation with continuously monitored tidal volumes.
Thus, despite the encouraging results seen in some previous controlled trials comparing HFV to tidal ventilation, it is unclear whether routine use of HFV offers any benefit to the VLBW infant who has received surfactant, would otherwise be ventilated with a patienttriggered mode of ventilation, and would be managed with continuous tidal volume monitoring.
We planned to conduct a large randomized multicenter trial comparing the early institution of HFOV to SIMV with continuous tidal volume monitoring in VLBW infants with RDS. In preparation for that trial, we performed this pilot study, which was designed to test the feasibility of the study protocol in a group of infants who would not be included in the larger study. We designed this pilot study to determine whether the ventilator management protocols for both the HFOV and SIMV arms could be implemented and followed in a number of different intensive care nurseries. Although determining the relative efficacy of the two ventilatory techniques was not a goal of the pilot study, we collected data on major neonatal outcomes. These included mortality, respiratory status at both 28 days and 36 weeks corrected age, age at extubation, number of surfactant doses, use of steroids to prevent or treat CLD, incidence of intraventricular hemorrhage (IVH), cystic periventricular leukomalacia (PVL), and incidence of patent ductus arteriosus (PDA).
MATERIALS AND METHODS
This pilot study enrolled 50 VLBW infants, from seven intensive care nurseries (see Acknowledgments), who were born between July and November of 1997. These seven nurseries were chosen because they had experience with HFOV and SIMV with tidal volume monitoring, were willing to follow strict ventilation protocols, and represented a diverse mixture of academic and community hospitals. The study design was reviewed and approved by the Institutional Review Board of each of the participating institutions. Informed parental consent was obtained for all study infants.
Infants were eligible for entry into the study if they met all of the following criteria: birth weight 501 to 1200 g, appropriate weight for gestational age, postnatal age 4 hours, had received one dose of surfactant, required mechanical ventilation with F I O 2 >0.25 and mean airway pressure 6 cm H 2 O, and were expected to require mechanical ventilation for more than 24 hours. Infants were excluded from the study if they had any of the following: obvious chromosomal or congenital anomalies, known significant congenital heart disease, seizures or known neuromuscular disease, severe asphyxia (defined as 5-minute Apgar score 3 or base deficit 15 at any point before study entry), or severe hypotension (defined as systolic arterial blood pressure greater than two standard deviations below the mean for birth weight despite dopamine and/or dobutamine with a total combined dose of 20 g/kg per minute).
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Eligible infants were stratified by birth weight (501 to 800, and 801 to 1200 g) and antenatal steroid status, and randomly assigned to receive either HFOV or SIMV. They were started on their assigned mode of ventilation at less than 4 hours of age with the plan to continue on the assigned mode of ventilation until reaching one of the following endpoints: death, successful extubation, or development of early CLD (defined as ventilator dependence at 28 days of age). Because the anticipated hypothesis of the planned large study did not involve comparison of HFOV and SIMV for patients with CLD, patients who were ventilator dependant at 28 days of age could be exited from the ventilator protocol and managed with other ventilatory strategies. All randomized infants remained in the study until death or discharge from the intensive care nursery. If a patient was treated with a mode of ventilation other than assigned, the patient remained in the study and was analyzed according to original ventilator assignment.
Ventilation Protocols
The ventilation protocols for both HFOV and SIMV were developed through extensive discussion between members of the Steering Committee (see Acknowledgments) as well as other neonatologists, respiratory therapists, and nurses experienced in the use of both modes of ventilation. The protocols were designed to provide a uniform philosophy and strategy for the management of VLBW infants that could be standardized both within and between institutions, and could easily be implemented by all care givers. From the beginning of the pilot study, it was clear that experience with the protocols would lead to successive clarifications and improvements. The protocols presented in the Appendix represent the final results of this clarification process.
HFOV was delivered with the SensorMedics 3100A (SensorMedics, Yorba Linda, CA). Because none of the other HFV devices currently available in the United States provide a similar oscillatory pattern, no other HFV devices were used in the nontidal arm. SIMV was delivered only with ventilators that provided flow-triggering and continuous tidal volume monitoring at the hub of the endotracheal tube. Three ventilators met these criteria: the VIP Bird (Bird Products, Palm Springs, CA), the Drager Babylog (North American Drager, Telford, PA), and the Bear Medical Bear Cub with the attached Neonatal Volume Monitor or the Bear Cub 750vs (Allied Health Care Products, Riverside, CA). To increase the similarity of the three SIMV ventilators, assist sensitivity was set at 0.2 l/min for all patients in the SIMV arm, and the termination sensitivity option on the VIP Bird was not used.
The underlying philosophy of the ventilator protocols emphasized initial recruitment of atelectatic alveoli, followed by aggressive weaning toward extubation. Optimizing lung inflation by avoiding under-and overinflation was an important element of the strategy. We estimated lung inflation on the basis of chest radiograph, using the location of the top of the right hemidiaphragm relative to the posterior ribs on an inspiratory chest radiograph to approximate the degree of lung inflation. Ideal lung inflation was defined for this study as between 8 and 9.5 ribs expansion for most patients, and between 7 and 8 ribs for patients with pulmonary interstitial emphysema (PIE) or other air leak. Assessment of heart size and diaphragm contours was also incorporated into the estimation of hyperinflation. For patients on SIMV, the target range for expiratory tidal volume was 5 to 6 ml/kg, with the option of using 4 ml/kg in the presence of hyperexpansion, and 7 ml/kg in the presence of atelectasis.
Arterial blood O 2 and CO 2 levels were maintained within identical target ranges in both groups. Arterial oxygen saturation, as measured by pulse oximeter, was maintained between 88% and 96%. A strategy of modest permissive hypercapnia (P a CO 2 40 to 55 Torr, 5.3 to 7.3 kPa) was used for most patients, with a higher degree of hypercapnia (P a CO 2 45 to 65 Torr, 5.9 to 8.7 kPa) accepted for patients who had PIE, pneumothorax, persistent significant hyperinflation, or obvious chronic changes on chest radiograph.
The protocols for both HFOV and SIMV included aggressive criteria for weaning ventilatory support and extubating infants. Patients were extubated, regardless of postnatal age or weight, as soon as they were stable for a period of 6 to 12 hours with an F I O 2 0.25 and a mean airway pressure 5 cm H 2 O on SIMV, or F I O 2 0.25 and a mean airway pressure 7 cm H 2 O on HFOV. This apparent difference in the mean airway is due to measurement artifact with the SensorMedics 3100A, which causes the measured proximal mean airway pressure to read approximately 1 to 2 cm H 2 O higher than the actual intrapulmonary mean airway pressure.
Other Aspects of Patient Care
The study protocol also dictated uniform treatment of patients in a number of areas that impact pulmonary and/or neurologic outcome. All patients were treated with the same surfactant (Survanta, Abbott Laboratories/Ross Products Division, Columbus, OH) with uniform criteria for redosing. All patients were treated with prophylactic indomethacin to potentially decrease their incidence of severe intracranial hemorrhage (ICH).
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To avoid alveolar derecruitment associated with disconnection of the endotracheal tube from the ventilator circuit, all suctioning was done with an in-line technique (Ballard Medical Products, Draper, UT). Similarly, all surfactant administration was performed using an in-line technique (Ballard Multi-Access Catheter).
Use of dexamethasone, diuretics, and bronchodilators for CLD was also standardized. Dexamethasone was started at 10 days of age for infants who were still ventilated with an F I O 2 0.3. The initial dose of dexamethasone was 0.5 mg/kg per day, and was decreased every three days, for a total course of 12 days. Patients who were greater than 28 days of age and were still ventilated with an F I O 2 0.4 were treated with diuretics and inhaled bronchodilators.
Assessing ICH and/or Cystic PVL Each patient had cranial ultrasounds performed at standard times (7 to 10, 21 to 28, and 50 to 60 days). These ultrasounds were reviewed by the radiologist at the study site, and scored according to a predetermined scale that evaluated ICH on a I to IV scale, as well as the presence or absence of cystic PVL. The ultrasounds were also sent to a single masked reviewer (D. A. M.) who scored them according to the same scale. The scores of the site radiologists and the single masked reviewer were then compared. If there was a difference between the scores assigned, the ultrasounds were sent to a third reviewer (L. N., also masked as to study group) who served as a tiebreaker.
Assessing Compliance With Ventilator Protocols
The primary goal of this pilot study was to determine how well the ventilator protocols could be followed. To determine this, we divided the ventilator course of each patient into successive 6-hour epochs, beginning with study entry and continuing until the patient was extubated or was exited from the ventilator protocol. For each epoch, a Yes/No score was assigned indicating whether the patient was managed according to the ventilator algorithms. This score was assigned by a single investigator (J. M. A.), in accordance with predetermined scoring rules. For each patient, the number of epochs that were scored as a``Yes,'' indicating management in complete agreement with the protocol, was then divided by the total number of epochs, giving a protocol compliance score for each patient.
RESULTS
Fifty patients were entered into the pilot study between July 12, 1997 and November 5, 1997. The status of the patients at time of study entry is shown in Table 1 . There were no apparent differences between the HFOV and SIMV patients. Two patients (twins) who were assigned to the HFOV arm were removed from the study at their parent's request. The remainder of the data presented is compiled from the 24 HFOV and 24 SIMV patients who completed the study.
This pilot study was not powered adequately to allow meaningful interpretation of outcome differences between groups. Therefore, we are reporting the outcome data but have chosen not to include statistical calculations that are not meaningful for such a small number of patients. Mortality and respiratory status at 36 weeks corrected age are shown in Table 2 . By 36 weeks corrected age, 19 of the 24 HFOV and 20 of the 24 SIMV infants were still alive. At both 28 days and at 36 weeks, infants in the HFOV group were more likely to be in room air (6/24 HFOV vs 3/24 SIMV at 14/24 HFOV vs 6/24 SIMV at 36 weeks). Other outcomes are shown in Table 3 , including the number of doses of surfactant, Values are either the number of patients or mean SD.
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Early HFOV vs. SIMV in VLBW Infants use of steroids for CLD, mean age at final extubation, and clinically significant PDA. Average fluid intake (milligrams per kilogram per day) for the first week of life for each group are also shown. Results of the neuro-ultrasound data are shown in Table  4 . The incidence of severe CNS abnormalities, defined as Grade III or IV ICH or cystic PVL, was similar between groups.
Although the intent of the study protocols was to maintain patients on their assigned mode of ventilation until they met one of the endpoints outlined in the study design, it soon became clear that this was not possible in all cases. In the first half of the pilot study, two patients exited from the HFOV ventilation protocol and five exited from the SIMV protocol at the discretion of their attending neonatologist. With successive revisions of the ventilator protocols, compliance improved. During the second half of the pilot study, no HFOV patient was exited, and only two SIMV patients were exited from the protocol.
Overall compliance with the ventilator management protocols (as defined above in Materials and Methods section) was excellent for patients in both study arms. For the SIMV patients 82% of the 6-hour epochs were in compliance; for HFOV patients 88% of the epochs were in compliance with the protocol.
DISCUSSION
There have been a number of prospective, randomized clinical trials comparing HFV to tidal ventilation for the treatment of premature infants. Most of these studies suggest that HFV offers significant clinical advantages. 11 ± 14,17,18 However, none of these studies has focused exclusively on infants less than 1200 g, the group of infants that accounts for the majority of ventilator days in most nurseries. All but three of these studies were conducted before surfactant therapy was introduced, and thus are of questionable relevance in today's clinical practice. None of these studies have compared nontidal ventilation to the newer patienttriggered modes of ventilation such as SIMV or assist-control (AC) with continuous tidal volume monitoring.
The decision to use SIMV rather than AC was based on the limited available data regarding the efficacy of AC in the VLBW infant. In addition, the Steering Committee felt that tidal volume monitoring was the most important factor in the design of the tidal ventilation arm of the study. Subsequently, Baumer. 29 has reported the results of the international randomized trial of AC versus IMV in 924 VLBW infants. This trial found no benefit from AC, and a trend toward more pneumothoraces in infants under 28 weeks who were randomized to AC.
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Tidal volume monitoring, if done, was not reported. Subsequent validation of lung-protective strategies in infants such as careful limiting of tidal volumes has been recently reviewed by Clark et al.
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, and confirmed to reduce mortality in adults. 31 We have undertaken the design and implementation of a large multicenter study that will compare the early use of HFOV with SIMV in VLBW infants. An essential part of the design process for the planned large trial was the development of strict ventilation protocols for both ventilator modes, because a wide range of ventilation strategies are currently in use for managing these infants. Despite the wide use of these modes of ventilation, there is little published data on the optimal strategy for using either HFOV or SIMV in VLBW infants. Not only do strategies differ between nurseries, but there are frequently wide variations in practice within the same nursery.
Thus, as we designed the HFOV and SIMV protocols, we were forced to make a number of decisions about ventilator strategy, often in the absence of adequate data from well-designed clinical trials. Although we attempted to base our choices on what limited published data are available, these protocols represent a consensus, based largely on ventilator philosophy and clinical experience, rather than knowledge of the single best way to manage these infants. For patients in the HFOV group, the primary goal was to optimize lung inflation by initially recruiting the lung, then avoiding the extremes of atelectasis or overdistension. 5 For patients in the SIMV group, the primary goal was to maintain tidal volumes within a narrow range to minimize potential damage occurring with lung overdistension by large tidal volumes.
32
In addition, both groups were managed with an aggressive approach to weaning and extubation. Throughout this pilot study, the staff of each site were extensively queried about how the study design and patient management could be improved. This led to several amendments in the ventilator protocols. These included the management of patients with severe lung disease, the approach to HFOV patients ventilated beyond 28 days of age, and modification of the dosage schedules for dexamethasone, diuretics, and bronchodilators. These revised protocols are being used in the large (n=500) multicenter study comparing early HFOV to SIMV in VLBW patients, which began July 1, 1998. The protocols presented in the Appendix represent the basic ventilation protocols but do not include the amendments for dealing with infants with severe lung disease or for those infants ventilated at greater than 28 days of age. We believe the protocols presented in the Appendix address ventilator management issues for the majority of VLBW infants. They are the result of several minor changes in the initial ventilatory protocols used in the pilot study, and are now being used in the large trial. These changes include requiring low ventilator flow rates (5 to 8 l/min for SIMV and 6 to 10 l/min for HFOV), using lower frequencies (10 to 12 Hz) in infants who develop hyperinflation on HFOV, and emphasizing the importance of maintaining infants in (or returning infants to) the target ranges of lung inflation, blood gases, and tidal volumes.
There is currently a great deal of interest in evidence-based patient management protocols, as well as some data suggesting that protocol-driven management improves care. 33, 34 We believe that the ventilation protocols we have developed are appropriate, based on our current understanding of the physiology of the VLBW infant. Based on the results of this pilot study, they also are easily implemented in a wide variety of clinical settings. With this in mind we present these protocols as two consistent approaches to the ventilatory management of the VLBW infant.
CONCLUSIONS
Data from our pilot study suggest possible respiratory benefits from early use of HFOV, and do not suggest an increase in ICH/PVL. However, we must emphasize that this pilot study was not powered to demonstrate differences in outcome. The apparent difference in number of patients in room air at 36 weeks corrected age and in incidence of PDA must be interpreted with extreme caution, given the small sample size. Similarly, the relationship between the treatment with HFOV, the apparent lower incidence of PDA, and the apparent higher incidence of survival without need for supplemental oxygen at 36 weeks must be interpreted with caution. Whether this was a causal relationship, or simply an artifact resulting from a small number of patients is unknown. Whether early HFV is superior to tidal ventilation for the management of VLBW infants is unknown at the present time, but should be determined by a large, appropriately powered multicenter study. Based on the results of this pilot study, which suggested that such a trial was feasible, we began enrolling 
APPENDIX
The underlying philosophy of the following protocols includes optimizing lung inflation, avoiding both atelectasis and overdistension, tolerating moderate hypercapnia, maintaining oxygen saturation within a narrow range, and aggressively weaning toward extubation. The frequency and magnitude of ventilator changes outlined in the protocol are initial guidelines; larger or more frequent ventilatory changes may be required to maintain infants in the target ranges. It is essential that every effort be made to rapidly return infants to the target ranges if they have``drifted'' outside these ranges.
Target Ranges for Blood Gas Values
Because the target ranges are fairly broad, weaning of ventilator settings is strongly encouraged for patients who have P a CO 2 values in the lower end of the target ranges. Likewise, weaning of patients with stable oxygenation is strongly encouraged. The target ranges for blood gases are as follows:
o Pulse oximeter saturation 88% to 96%; o pH7.25. o P a CO 2 40 to 55 Torr in patients without PIE, gross air leak, hyperinflation, chronic changes on chest X -ray (CXR ); o P a CO 2 45 to 65 Torr in patients with PIE, gross air leak, hyperinflation, or chronic changes on CXR;
Target Ranges for Lung Inflatioǹ`I deal'' lung inflation is defined as the top margin of the dome of the right hemidiaphragm located between the bottom of the eighth rib and no more than midway between the ninth and tenth ribs. The major focus will be avoidance of atelectasis and hyperinflation. In addition to overexpansion, small heart and flat diaphragms may also indicate hyperinflation. Patients with PIE or AL will be managed with a low-lung-volume strategy, defined as diaphragm level between the seventh and eighth ribs.
Nontidal Volume Ventilation Strategy (HFOV)
Initial HFOV settings. Initiate HFOV at these settings: Adjusting SIMV settings to achieve optimal lung inflation. All of the following changes assume that the exhaled tidal volume is in the target range of 4 to 7 ml/kg. If the dome of the right diaphragm is: SIMV management of PIE and/or gross air leak with lowlung-volume strategy.
o If the infant has PIE or gross air leak such as pneumothorax or pneumomediastinum, change to a low -lung -volume strategy (diaphragm level between seventh and eighth ribs ) accepting whatever F I O 2 is necessary to maintain target blood gases, until the air leak has resolved for 24 hours. o If the infant has unilateral PIE, he /she should be positioned with affected side down ( at 90 -degree angle to bed ). Attempt to keep the infant primarily in this position until PIE is resolved. o Once PIE and /or gross air leak has resolved, return to optimal lung volume strategy. Patients with PIE and /or gross air leak should be managed with a higher target P a CO 2 range (e.g., 45 to 65 Torr ).
SIMV management of patient with hyperinflation and/or CLD.
o Some patients with early CLD have relative hyperinflation. This should be treated by aggressive weaning of PEEP and /or PIP, as well as by accepting a higher target P a CO 2 range ( e.g., 45 to 65 Torr ). o If infant is hyperinflated with a tidal volume of 4 ml /kg and high respiratory rate ( > 40 breaths /min ), consider decreasing T insp by 0.05 second; o Patients with obvious CLD changes on chest radiograph should also be treated by accepting a higher target P a CO 2 range ( e.g., 45 to 65 Torr ).
Weaning SIMV. The goal is to aggressively wean infants toward extubation.
o If P a CO 2 remains in target range for > 12 hours and patient is stable, wean rate and /or PIP by 10%. However, if P a CO 2 is > 50 cm H 2 O (with normal inflation on CXR ) or > 60 cm H 2 0 (with hyperinflation on CXR ), weaning is optional; o Weaning may be attempted more frequently than every 12 hours.
Extubation and Reintubation
Extubation will be attempted as soon as the patient is stable on minimal ventilator settings without excess work of breathing.
Extubation will be attempted when patient meets both the following criteria: Patients who remain stable on these minimal ventilator settings for 6 to 12 hours should be extubated.
Before extubation, infants will be treated with caffeine or theophylline, as prophylaxis for apnea and bradycardia. Infants will be extubated to nasal CPAP (NCPAP) of 4 to 6 cm H 2 O (using the Aladdin or Infant-Flow NCPAP system). Patients with the following should be reintubated:
o Need for more than 8 cm H 2 O of nasal CPAP and F I O 2 > 0.50 to maintain pulse oximeter saturation in the target range of 88% to 96%; o P a CO 2 > 65 and pH < 7.25; o Recurrent apnea and /or bradycardia resulting in oxygen saturation < 85%;
